These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29093399)

  • 1. The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial.
    Moriyama T; Kumon S; Kamiyama T; Karasawa K; Uchida K; Nitta K
    Intern Med; 2018 Jan; 57(2):173-179. PubMed ID: 29093399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
    Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
    J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
    Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC;
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
    Crandell JR; Tartaglia C; Tartaglia J
    Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.
    Singh S; Arora RR; Singh M; Khosla S
    Am J Ther; 2016; 23(3):e905-10. PubMed ID: 25828517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
    Jacobson TA; Glickstein SB; Rowe JD; Soni PN
    J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
    Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combination therapy with renin-angiotensin system inhibitors and eicosapentaenoic acid on IgA nephropathy.
    Moriyama T; Iwasaki C; Tanaka K; Ochi A; Shimizu A; Shiohira S; Itabashi M; Takei T; Uchida K; Tsuchiya K; Nitta K
    Intern Med; 2013; 52(2):193-9. PubMed ID: 23318848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of mycotoxin-induced IgA nephropathy by eicosapentaenoic acid in the mouse: dose response and relation to IL-6 expression.
    Shi Y; Pestka JJ
    J Nutr Biochem; 2006 Oct; 17(10):697-706. PubMed ID: 16524712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review.
    Innes JK; Calder PC
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29425187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexaenoic acid and eicosapentaenoic acid, but not alpha-linolenic acid, suppress deoxynivalenol-induced experimental IgA nephropathy in mice.
    Jia Q; Shi Y; Bennink MB; Pestka JJ
    J Nutr; 2004 Jun; 134(6):1353-61. PubMed ID: 15173396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM; Ferraccioli GF; Gambaro G; Fulignati P; Costanzi S
    Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of low-dose docosahexaenoic acid and eicosapentaenoic acid on the regulation of mitogenic signaling pathways in mesangial cells.
    Yusufi AN; Cheng J; Thompson MA; Walker HJ; Gray CE; Warner GM; Grande JP
    J Lab Clin Med; 2003 May; 141(5):318-29. PubMed ID: 12761475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid.
    Allaire J; Harris WS; Vors C; Charest A; Marin J; Jackson KH; Tchernof A; Couture P; Lamarche B
    Prostaglandins Leukot Essent Fatty Acids; 2017 May; 120():8-14. PubMed ID: 28515020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.
    Schwellenbach LJ; Olson KL; McConnell KJ; Stolcpart RS; Nash JD; Merenich JA;
    J Am Coll Nutr; 2006 Dec; 25(6):480-5. PubMed ID: 17229894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of plant sterols and different low doses of omega-3 fatty acids from fish oil on lipoprotein subclasses.
    Jacobs DM; Mihaleva VV; van Schalkwijk DB; de Graaf AA; Vervoort J; van Dorsten FA; Ras RT; Demonty I; Trautwein EA; van Duynhoven J
    Mol Nutr Food Res; 2015 Sep; 59(9):1745-57. PubMed ID: 26019023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein.
    Mesa MD; Buckley R; Minihane AM; Yaqoob P
    Atherosclerosis; 2004 Aug; 175(2):333-43. PubMed ID: 15262190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy.
    Donadio JV; Larson TS; Bergstralh EJ; Grande JP
    J Am Soc Nephrol; 2001 Apr; 12(4):791-799. PubMed ID: 11274240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.